News from mind medicine (mindmed) inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 09, 2023, 07:30 ET MindMed Provides Corporate Update and 2023 Outlook

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Nov 11, 2022, 07:30 ET MindMed to Participate in the Jefferies London Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Nov 10, 2022, 08:05 ET MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Nov 03, 2022, 07:30 ET MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Oct 05, 2022, 08:35 ET MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Oct 04, 2022, 07:30 ET MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Sep 27, 2022, 23:47 ET MindMed Announces Pricing of Public Offering of Common Shares and Warrants

Mind Medicine (MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat...

Sep 27, 2022, 16:17 ET MindMed Announces Proposed Public Offering of Common Shares

Mind Medicine (MindMed) Inc. ("MindMed") (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat...

Sep 20, 2022, 07:30 ET MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Sep 14, 2022, 07:30 ET MindMed Announces Compliance with Nasdaq Listing Requirements

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Sep 08, 2022, 07:30 ET MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Sep 07, 2022, 07:30 ET MindMed to Participate in H.C. Wainwright Global Investment Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Aug 26, 2022, 16:30 ET MindMed Completes 1-for-15 Reverse Share Split

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Aug 25, 2022, 07:30 ET MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Aug 12, 2022, 07:30 ET MindMed Strengthens Board with Appointment of Two New Independent Directors

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to...

Aug 11, 2022, 16:06 ET MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

– Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 – – Advanced...

Aug 04, 2022, 17:30 ET MindMed Board of Directors Approves Reverse Share Split

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Aug 04, 2022, 07:30 ET MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Aug 02, 2022, 07:30 ET MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

Jun 01, 2022, 17:30 ET Mindmed Announces Voting Results for Annual General and Special Meeting

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general...

Jun 01, 2022, 07:59 ET MindMed to Participate in the Jefferies Global Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

May 23, 2022, 07:30 ET MindMed Appoints Schond L. Greenway as Chief Financial Officer

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

May 19, 2022, 07:30 ET MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...

May 16, 2022, 07:30 ET MindMed Reports First Quarter 2022 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to...

May 12, 2022, 07:30 ET MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel...